Pipeline
Drug Candidate
Indication
IND-enabling
Phase 1
Phase 2
Phase 3
Oral
Formulation*
Drug Designation**
Cardiol has received IND authorization from the U.S. FDA to conduct a Phase II open-label pilot study designed to evaluate the tolerance, safety, and disease endpoints of CardiolRx™ in patients with recurrent pericarditis – the most common of pericardial diseases with symptoms that include debilitating chest pain, shortness of breath, and fatigue. Learn more…
CardiolRx™ is currently being evaluated in a Phase II multi-national clinical study, the ARCHER trial, to evaluate the safety and tolerability as well as its impact on myocardial recovery, in patients presenting with acute myocarditis – an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in people less than 35 years of age. Learn more…
Subcutaneous
Formulation*
Cardiol is developing a subcutaneous formulation of cannabidiol targeting the inflammation and fibrosis associated with the development and progression of heart failure – a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the U.S. exceeding $30 billion annually. Learn more…
*Active pharmaceutical ingredient = cannabidiol
**The Company intends to seek Orphan Drug Designation for CardiolRx for acute myocarditis and recurrent pericarditis
